Home > Dermatology > SPIN 2022 > Psoriasis: The Beat Goes On > Greater PASI reductions lead to less impairment in social and sexual life

Greater PASI reductions lead to less impairment in social and sexual life

Conference
SPIN 2022
Trial
Phase 3, VOYAGE 1, VOYAGE 2
Doi
https://doi.org/10.55788/e8bdb727
Both therapies with guselkumab and adalimumab improved social relationships and sexual health in patients with psoriasis compared with placebo at week 12. At week 24, guselkumab was superior to adalimumab regarding the improvement of social relationships and sexual health. Data on the association of social relationships and sexual health with different psoriasis treatments is scarce. Therefore, an analysis of phase 3, randomised, double-blind VOYAGE 1 and 2 trials (NCT02207231 and NCT02207244) assessed the influence of therapy with guselkumab or adalimumab on social relationships and sexual difficulties in patients with psoriasis [1]. Impairment in these domains was assessed with questions 8 and 9 of the Dermatology Life Quality Index (DLQI) (being question 8 the following...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on